Tissium has raised $68 million (€60 million) through a combination of a $34 million Series D2 financing and a $34 million financing facility from the European Investment Bank (EIB).
The funding comes as the company advances the commercialization of Coaptium Connect with Tissium Light, its FDA-authorized, sutureless solution for peripheral nerve repair, while continuing development of products for nerve repair, hernia repair, and cardiovascular applications.
Related: CroíValve closes expanded Series B at $36M
Tissium plans to use the proceeds to support commercial expansion, clinical programs, pipeline development, and further advancement of its proprietary biomorphic polymer platform.
CEO and co-founder Christophe Bancel said:
“Following the FDA marketing authorization of Coaptium Connect, we are now executing on our transition into a commercial-stage medtech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform.”
He added that the financing provides the company with the resources and flexibility needed to accelerate commercialization while investing in future growth opportunities.
The funding marks a significant step in Tissium’s transition from development-stage innovator to commercial medtech company.
